Abstract: An avatar motion generating method and a head mounted display system are provided. In the method, an input event is received, and the input event is related to sensing result of a user. First avatar motion is generated based on one of predefined motion data, motion sensing data and a combination thereof at the first period of time. Second avatar motion is generated based on another of the predefined motion data, the motion sensing data and the combination thereof at the second period of time. Accordingly, the motion of the avatar could be smooth and natural.

Abstract: An avatar motion generating method and a head mounted display system are provided. In the method, an input event is received, and the input event is related to sensing result of a user. First avatar motion is generated based on one of predefined motion data, motion sensing data and a combination thereof at the first period of time. Second avatar motion is generated based on another of the predefined motion data, the motion sensing data and the combination thereof at the second period of time. Accordingly, the motion of the avatar could be smooth and natural.

Abstract: A method for matrix by vector multiplication, applied in an artificial neural network system, is disclosed. The method comprises: compressing a plurality of weight values in a weight matrix and indices of an input vector into a compressed main stream; storing M sets of synapse values in M memory devices; and, performing reading and MAC operations according to the M sets of synapse values and the compressed main stream to obtain a number M of output vectors. The step of compressing comprises: dividing the weight matrix into a plurality of N×L blocks; converting entries of a target block and corresponding indices of the input vector into a working block and an index matrix; removing zero entries in the working block; shifting non-zero entries row-by-row to one of their left and right sides in the working block; and, respectively shifting corresponding entries in the index matrix.

Abstract: The present invention provides a method to treat asthma and airway allergy by administering the dipeptide cyclo tyrosine-valine or a related cyclodipeptide compound to a subject in need thereof. Cyclo tyrosine-valine or the related cyclodipeptide compound reduces Th2 cell activation, airway hyperresponsiveness, accumulation of immune cells in bronchoalveolar fluid, and allergen-specific antibody production in an animal or human subject. The compound can therefore be used to treat asthma and airway allergy.

Abstract: A noise cancellation device includes an anti-noise filter circuit, an output circuit, and a detection circuit. The anti-noise filter circuit provides a corresponding one of transfer functions to process a digital signal, in order to generate a noise cancellation signal, in which the transfer functions are different from each other. The output circuit mixes the noise cancellation signal, a reference signal, and an input signal to generate a mixed signal, and generates a sound output signal based on the mixed signal, in which the digital signal is associated with the sound output signal. The detection circuit controls the anti-noise filter circuit to provide the corresponding one of the transfer functions according to a comparison result of a first ratio and a first threshold value, in which the first ratio is a ratio of a first power of the mixed signal to a second power of the digital signal.

Abstract: A method for matrix by vector multiplication, applied in an artificial neural network system, is disclosed. The method comprises: compressing a plurality of weight values in a weight matrix and indices of an input vector into a compressed main stream; storing M sets of synapse values in M memory devices; and, performing reading and MAC operations according to the M sets of synapse values and the compressed main stream to obtain a number M of output vectors. The step of compressing comprises: dividing the weight matrix into a plurality of N×L blocks; converting entries of a target block and corresponding indices of the input vector into a working block and an index matrix; removing zero entries in the working block; shifting non-zero entries row-by-row to one of their left and right sides in the working block; and, respectively shifting corresponding entries in the index matrix.

Abstract: An audio processing device includes a first anti-noise filter, an output circuit, and an equalizer circuit. The first anti-noise filter is configured to process a digital signal, in order to generate a noise cancellation signal. The output circuit is configured to mix the noise cancellation signal with an equalized signal to generate a mixed signal, and to generate a sound output signal based on the mixed signal, in which the digital signal is associated with the sound output signal. The equalizer circuit is configured to receive an input signal, and to adjust at least one parameter of the equalizer circuit according to the equalized signal and the digital signal, in order to process the input signal to generate the equalized signal.

Abstract: Disclosed herein are compounds, compositions and methods for treating tumors, particularly tumors that metastasize, via inhibiting tumor cells-induced platelet aggregation. The compound of the present disclosure has the formula (I), wherein, n is 2 or 3.

Abstract: An audio processing device includes a first anti-noise filter, an output circuit, and an equalizer circuit. The first anti-noise filter is configured to process a digital signal, in order to generate a noise cancellation signal. The output circuit is configured to mix the noise cancellation signal with an equalized signal to generate a mixed signal, and to generate a sound output signal based on the mixed signal, in which the digital signal is associated with the sound output signal. The equalizer circuit is configured to receive an input signal, and to adjust at least one parameter of the equalizer circuit according to the equalized signal and the digital signal, in order to process the input signal to generate the equalized signal.

Abstract: A noise cancellation device includes an anti-noise filter circuit, an output circuit, and a detection circuit. The anti-noise filter circuit provides a corresponding one of transfer functions to process a digital signal, in order to generate a noise cancellation signal, in which the transfer functions are different from each other. The output circuit mixes the noise cancellation signal, a reference signal, and an input signal to generate a mixed signal, and generates a sound output signal based on the mixed signal, in which the digital signal is associated with the sound output signal. The detection circuit controls the anti-noise filter circuit to provide the corresponding one of the transfer functions according to a comparison result of a first ratio and a first threshold value, in which the first ratio is a ratio of a first power of the mixed signal to a second power of the digital signal.

Abstract: Disclosed are 5-nitrobenzoate derivatives of Formula I, and the preparation method therefor, wherein R is referred to hydrogen (H), unsubstituted, mono-substituted, di-substituted or tri-substituted benzoyl moiety. 5-Nitrobenzoare derivatives of Formula I do not affect the platelet aggregation, possesses the inhibitory activity related to the tumor cell-induced platelet aggregation (TCIPA), and further specifically inhibits podoplanin-induced platelet aggregation. Therefore, 5-nitrobenzoates of the invention are applicable in its therapeutic use as the novel therapeutic agent in preventing tumor metastasis.

Abstract: The invention relates to a use of an aurantiamide dipepetide derivative in the treatment or prevention of angiogenesis-related diseases. Accordingly, aurantiamide dipeptide derivatives can be used as angiogenesis inhibitor, whereby preventing or treating invasive and metastatic cancer and ocular neovascularization (particularly macular degeneration such as pathological neovascularization of age-related macular degeneration (AMD)).

Abstract: The invention relates to a use of an aurantiamide dipepetide derivative in the treatment or prevention of angiogenesis-related diseases. Accordingly, aurantiamide dipeptide derivatives can be used as angiogenesis inhibitor, whereby preventing or treating invasive and metastatic cancer and ocular neovascularization (particularly macular degeneration such as pathological neovascularization of age-related macular degeneration (AMD)).

Abstract: Disclosed herein are compounds, compositions and methods for treating tumors, particularly tumors that metastasize, via inhibiting tumor cells-induced platelet aggregation. The compound of the present disclosure has the formula (I), wherein, n is 2 or 3.

Abstract: Disclosed are 5-nitrobenzoate derivatives of Formula I, and the preparation method therefor, wherein R is referred to hydrogen (H), unsubstituted, mono-substituted, di-substituted or tri-substituted benzoyl moiety. 5-Nitrobenzoare derivatives of Formula I do not affect the platelet aggregation, possesses the inhibitory activity related to the tumor cell-induced platelet aggregation (TCIPA), and further specifically inhibits podoplanin-induced platelet aggregation. Therefore, 5-nitrobenzoates of the invention are applicable in its therapeutic use as the novel therapeutic agent in preventing tumor metastasis.

Abstract: Disclosed are 5-nitrobenzoate derivatives of Formula I, and the preparation method therefor, wherein R is referred to hydrogen (H), unsubstituted, mono-substituted, di-substituted or tri-substituted benzoyl moiety. 5-Nitrobenzoare derivatives of Formula I do not affect the platelet aggregation, possesses the inhibitory activity related to the tumor cell-induced platelet aggregation (TCIPA), and further specifically inhibits podoplanin-induced platelet aggregation. Therefore, 5-nitrobenzoates of the invention are applicable in its therapeutic use as the novel therapeutic agent in preventing tumor metastasis.

Abstract: A dipeptide derivative as formyl peptide receptor 1 (FPR1) antagonist is provided. The dipeptide derivative is represented by formula (I), wherein: the chiral centers in formula (I) are S and R configurations respectively; each of RK and RT is selected from a group consisting of a hydrogen, a hydroxyl group, a C1-C4 alkyl-substituted hydroxyl group, a C1-C4 alkoxyl group, a carboxylic acid group, a C1-C4 alkyl nitrile-substituted, C1-C4 alkyl-substituted or C1-C4 alkoxyl-substituted amido group, a C1-C4 alkyl-substituted ester group and a benzoyl group having a C1-C4 alkyl-substituted benzene ring; and each of RM and RS is selected from a group consisting of a hydrogen, a hydroxyl group, a phenyl group, a pyridinyl group, a carboxylic acid group, a C1-C4 alkoxyl substituted ester group, and a benzoyl group having a hydroxyl-substituted, a halogen-substituted, a C1-C4 alkoxyl-substituted or a C1-C4 alkyl-substituted benzene ring.

Abstract: A dipeptide derivative as formyl peptide receptor 1 (FPR1) antagonist is provided. The dipeptide derivative is represented by formula (I), wherein: the chiral centers in formula (I) are S and R configurations respectively; each of RK and RT is selected from a group consisting of a hydrogen, a hydroxyl group, a C1-C4 alkyl-substituted hydroxyl group, a C1-C4 alkoxyl group, a carboxylic acid group, a C1-C4 alkyl nitrile-substituted, C1-C4 alkyl-substituted or C1-C4 alkoxyl-substituted amido group, a C1-C4 alkyl-substituted ester group and a benzoyl group having a C1-C4 alkyl-substituted benzene ring; and each of RM and RS is selected from a group consisting of a hydrogen, a hydroxyl group, a phenyl group, a pyridinyl group, a carboxylic acid group, a C1-C4 alkoxyl substituted ester group, and a benzoyl group having a hydroxyl-substituted, a halogen-substituted, a C1-C4 alkoxyl-substituted or a C1-C4 alkyl-substituted benzene ring.

Abstract: An oxime-based compound having the following formula (I) or a pharmaceutically acceptable salt thereof: wherein: Y is a carbonyl group or a sulfonyl group; R1 is selected from H, OH, a C1-C4 alkyl group, and a C1-C4 alkoxyl group; R2 is selected from OH, a methoxyl group, —OR4OH, and —OR4NH2, R4 being a C1-C3 alkyl group; and R3 is H or a pivaloyloxybenzenesulfonyl group.

Abstract: An oxime-based compound having the following formula (I) or a pharmaceutically acceptable salt thereof: wherein: Y is a carbonyl group or a sulfonyl group; R1 is selected from H, OH, a C1-C4 alkyl group, and a C1-C4 alkoxyl group; R2 is selected from OH, a methoxyl group, —OR4OH, and —OR4NH2, R4 being a C1-C3 alkyl group; and R3 is H or a pivaloyloxybenzenesulfonyl group.